Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 7/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644947 | 1.00 | KMT2A (0.39) | KMT2AALDH1A1MEN1NPSR1L3MBTL1 | |
| SCHEMBL26623490 | 1.00 | KMT2A (0.39) | KMT2AALDH1A1MEN1NPSR1L3MBTL1 | |
| SCHEMBL3469761 | 1.00 | KMT2A (0.39) | KMT2AALDH1A1MEN1NPSR1L3MBTL1 | |
| SCHEMBL3470477 | 0.89 | TSHR (0.36) | KMT2AALDH1A1TSHRGRM2GRM3 | |
| SCHEMBL3470242 | 0.86 | CASP3 (0.32) | TSHRCASP1CASP3CASP8 | |
| SCHEMBL3470055 | 0.86 | KCNA3 (0.34) | KMT2AALDH1A1MEN1CASP1CASP3 | |
| SCHEMBL10263107 | 0.86 | KCNA3 (0.34) | KMT2AALDH1A1MEN1CASP1CASP3 | |
| SCHEMBL646854 | 0.86 | KCNA3 (0.34) | KMT2AALDH1A1MEN1CASP1CASP3 | |
| SCHEMBL3472119 | 0.85 | MEN1 (0.32) | KMT2AMEN1 | |
| SCHEMBL3470257 | 0.83 | CASP1 (0.35) | KMT2AALDH1A1MEN1NPSR1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048306-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-02-13 | — | — | US | disclosed |
| US-9994613-B2 | Prodrug of an ICE inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994613-B2 | Prodrug of an ICE inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170022249-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2017-01-26 | — | — | US | disclosed |
| US-20170022249-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2017-01-26 | — | — | US | disclosed |
| US-9487555-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487555-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-08 | — | — | US | disclosed |
| US-9156880-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156880-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150284426-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-08 | — | — | US | disclosed |
| US-20110301096-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-08 | — | — | US | disclosed |
| US-8022041-B2 | Prodrug of an ICE inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022041-B2 | Prodrug of an ICE inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110059018-A1 | COVALENTLY BINDING IMAGING PROBES | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| EP-2262783-A2 | COVALENTLY BINDING IMAGING PROBES | Sanofi-Aventis (FR) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009103432-A2 | COVALENTLY BINDING IMAGING PROBES | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | WO | disclosed |
| US-20090012149-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
| US-20090012149-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
| US-7417029-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417029-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048306-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | KMT2A 3551/4885ALDH1A1 287/4885MEN1 418/4885 |
| US-20090012149-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | KMT2A 3551/4885ALDH1A1 287/4885MEN1 418/4885 |
| US-20110059018-A1 | COVALENTLY BINDING IMAGING PROBES | CTSV, CTSL, CTSE | KMT2A 3834/4885ALDH1A1 1016/4885MEN1 1935/4885 |
| US-20110301096-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | KMT2A 3551/4885ALDH1A1 287/4885MEN1 418/4885 |
| US-20170022249-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | KMT2A 3551/4885ALDH1A1 287/4885MEN1 418/4885 |
| US-20150284426-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | KMT2A 3551/4885ALDH1A1 287/4885MEN1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.